Overview

The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
0
Participant gender:
Male
Summary
The purpose of this study is to investigate the effect of low-dose human growth hormone therapy on immune status and fat morphology.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hvidovre University Hospital
Collaborator:
Pfizer
Treatments:
Hormones
Criteria
Inclusion Criteria:

- Male

- Caucasian race

- Age >21 years, <60 years

- HIV-1 infection

- HAART treated > 12 months

- HIV-RNA < 100 copies/ml

- CD4 count > 200

- Fasting plasma glucose < 6.1 mM

- Stable weight

Exclusion Criteria:

- BMI > 28 kg/m2 and BMI < 18.5 kg/m2

- Wasting or AIDS defining disease

- Severe chronic diseases other than HIV

- Cancer, previous transplantation

- Previous AMI

- Diabetes

- Hormonal substitution therapy

- Lipid lowering or antidiabetic therapy within 3 months

- Abuse of narcotics or alcohol

- Major psychiatric disorders

- Adverse reactions towards Genotropin

- Calcium-ion < 1.15 or > 1.35 mM

- D-vitamin < 19 nM

- TSH < 0.1 or > 10 mIU/l